Novo has shared an encouraging CMD update, supporting healthy growth across focus areas. This is particularly true for Wegovy (new obesity drug), where Novo is confident of resolving supply issues by Q2 22. While on-track development of pipeline programmes outside diabetes was the icing on the cake, it is unlikely to result in near-term operating gains. Overall, our estimates should reset higher, but the cautious stance – citing a high valuation and no major near-term readouts – should be mainta ....
04 Mar 2022
Takeaways from 2022 Capital Markets Day
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Takeaways from 2022 Capital Markets Day
- Published:
04 Mar 2022 -
Author:
Amandeep Goyal -
Pages:
4
Novo has shared an encouraging CMD update, supporting healthy growth across focus areas. This is particularly true for Wegovy (new obesity drug), where Novo is confident of resolving supply issues by Q2 22. While on-track development of pipeline programmes outside diabetes was the icing on the cake, it is unlikely to result in near-term operating gains. Overall, our estimates should reset higher, but the cautious stance – citing a high valuation and no major near-term readouts – should be mainta ....